The Clinical Frontier · 16 October 2026 · Issue 029 Anthropic just gave an independent evaluator the right to publish its AI safety findings without a vendor veto. India’s clinical AI ecosystem needs the same structure before deployment.
In this issue
- On October 15, 2026, Anthropic published an update on its independent evaluator programme, formalising three tiers of third-party access to its AI systems.
- METR, now embedded at Tier 3, has employee-level access to Anthropic’s hardware, office space, and internal tools and can publish its safety findings without Anthropic’s approval.
- India is deploying clinical AI at scale across ABDM, PM-JAY, and hospital diagnostic workflows, with no standardised framework for independent evaluation of those tools before deployment.
- The Anthropic-METR structure is a concrete, adoptable template for what clinical AI accountability in India should look like.
The signal
On October 15, 2026, Anthropic published an update on its independent evaluator programme. The announcement formalises a three-tier structure for outside organisations to evaluate Anthropic’s AI systems, and establishes the deepest form of that access for the first time.
At Tier 3, the evaluation organisation METR now has employee-level access inside Anthropic: company hardware, office space, and internal tools and systems. Six METR staff work with this access. METR publishes its analyses of Anthropic’s risk levels, incidents, and practices. Critically, Anthropic cannot veto publication. It can require redactions in narrow, defined categories: customer data, privileged legal information, and model architecture details. METR retains the right to publicly state whether it considers those redactions justified.
Two other organisations are involved at adjacent tiers. SecureBio is reviewing the chemical and biological weapons chapter of Anthropic’s August 2026 Risk Report; Anthropic intends to consider broader access after this review is complete. Accenture and Faculty are in a broader partnership covering model evaluation, red-teaming, alignment assessment, and safeguard testing.
Anthropic frames the arrangement using a direct analogy: a bank examiner embedded inside a large bank. The examiner has real access; the bank cannot edit the report before it goes out.
How the three tiers map to clinical AI
The tier structure is worth unpacking because it maps cleanly onto the kinds of clinical AI evaluation that Indian health systems actually need.
Tier 1 is a narrowly scoped investigation where the vendor defines the access and publication requires the vendor’s approval. This describes most of what passes for “validation” in the clinical AI market today: the vendor provides a curated demo environment, the hospital’s clinical informatics team reviews a summary, and the vendor decides what gets released. It is documentation theatre, not independent evaluation.
Tier 2 gives the evaluator broader access to actual information, with publication rights and no vendor veto, subject only to narrow exceptions. An evaluator operating at this tier can assess real systems, real training data, and real performance metrics, not just the approved slides.
Tier 3, the METR arrangement, goes furthest: employee-level access to hardware and internal systems, and the same publication rights as Tier 2, with the additional structural guarantee that the evaluator can go public about any redaction it considers unjustified. The vendor cannot hide findings by invoking a blanket confidentiality clause.
The key design principle across all three tiers is that the evaluator’s independence is structural, not just contractual. A contractual independence that still requires vendor approval to publish is no independence at all.
Why India needs this for clinical AI
India is deploying AI-assisted clinical tools faster than its evaluation infrastructure is being built. That gap is now large enough to matter for patient safety.
The PM-JAY pre-authorisation workflow. The National Health Authority has been piloting AI in the PM-JAY claims and pre-authorisation process. An AI tool that influences whether a hospitalisation claim is approved, denied, or pended is making a decision that directly affects a patient’s access to care. The Indian population’s disease mix, its distribution of co-morbidities, and the documentation quality of hospitals serving low-income patients are not well-represented in the training data of most international clinical AI models. Whether a specific tool’s outputs are fair and calibrated for Indian patients is exactly the question a Tier 2 evaluator with training data access should be answering, before the tool goes live in a PM-JAY workflow.
Diagnostic AI in the ABDM stack. The Ayushman Bharat Digital Mission is building the national digital health record infrastructure on FHIR-based standards. Diagnostic AI tools are increasingly being integrated into ABDM-linked workflows, from radiology flagging to chronic disease management prompts. Without an independent evaluation standard, the only check on whether those tools work as claimed is the vendor’s own technical documentation, which CDSCO’s Software as Medical Device guidance framework may require but cannot by itself verify.
The CDSCO SaMD gap. India’s medical device regulator has been developing guidance on software as a medical device, covering AI-enabled tools under the Medical Devices Rules, 2017. The international direction for AI medical device regulation, including approaches taken by the US FDA and the EU, requires manufacturers to document training data composition, demonstrate performance across relevant subpopulations, and maintain post-market surveillance. Regulatory guidance of this kind creates a documentation requirement. What it does not yet create in India is a mechanism for an independent party, with real system access and guaranteed publication rights, to verify that the documentation matches the actual system.
What the Anthropic model suggests for India
Anthropic’s programme is a template, not just a news item.
Match the tier to the risk level. A wellness chatbot for appointment reminders does not require the same level of independent evaluation as an AI diagnostic tool used to guide treatment in a tertiary hospital. India can adopt a tiered framework: lower-risk AI tools require documentation review and summary publication rights, higher-risk tools (diagnostic AI, PM-JAY adjudication, surgical guidance) require access to training data, real-world performance metrics, and evaluator publication rights without vendor veto.
Build structural independence into the framework. Evaluators operating under vendor approval conditions are not independent evaluators. Any Indian clinical AI evaluation framework should specify, as a condition of Tier 2 and Tier 3 access, that the evaluator’s findings can be published without the vendor’s approval, subject only to defined and narrow exceptions that the evaluator can publicly dispute.
Use existing Indian institutions. India does not need to create an evaluation body from scratch. ICMR-affiliated academic hospitals have the clinical expertise to evaluate AI tool performance in Indian patient populations. IIT and AIIMS informatics groups have the technical capability to assess model architecture documentation, training data composition, and bias metrics. CDSCO can require independent evaluation as a condition of market authorisation for high-risk AI medical devices, as it already requires clinical evidence for pharmaceutical products.
NHA as the deployment-oversight anchor. For AI embedded in the ABDM and PM-JAY stacks, the National Health Authority is the right body to define the evaluation standard before procurement. A vendor bidding for an AI role in a public health programme should be expected to demonstrate that an independent evaluator with real access has assessed their tool against criteria the NHA sets.
The takeaway
Anthropic’s October 15 announcement is significant not because it is unique to Anthropic but because it makes the structure explicit and public. Employee-level evaluator access, structural publication rights without vendor veto, and a risk-matched tier framework: these are not AI-company-specific features. They are the accountability infrastructure that any high-stakes AI deployment, including clinical AI in India, has been missing.
India’s health AI governance ecosystem has the institutions, the regulatory foundation, and the deployment scale to make this real. The question is whether the next procurement cycle for PM-JAY AI tools, the next ABDM integration approval, or the next CDSCO SaMD market authorisation requires it.
A vendor who cannot pass an independent evaluation should not be in a patient-facing workflow. That standard is now on the table.
The Clinical Frontier is a daily briefing from HCITExperts for India’s health-IT community. Primary source: An update on independent evaluators (Anthropic, 15 October 2026). More tomorrow.